QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlook
QIAGEN reported strong Q3 2024 results with net sales of $502 million, representing a 5% increase at actual rates and 6% at constant exchange rates (CER), exceeding the outlook of $495 million CER. The company achieved a 29.6% adjusted operating income margin, up 3 percentage points from Q3 2023. Free cash flow increased 73% to $364 million in the first nine months of 2024. Based on solid performance, QIAGEN reaffirmed its FY 2024 net sales outlook of at least $1.985 billion CER and increased its adjusted diluted EPS outlook to at least $2.19 CER from the previous $2.10 CER.
QIAGEN ha riportato risultati solidi per il terzo trimestre del 2024, con vendite nette di 502 milioni di dollari, che rappresentano un aumento del 5% ai tassi attuali e del 6% ai tassi di cambio costanti (CER), superando la previsione di 495 milioni di dollari CER. L'azienda ha raggiunto un margine di reddito operativo rettificato del 29,6%, in aumento di 3 punti percentuali rispetto al terzo trimestre del 2023. Il flusso di cassa libero è aumentato del 73%, arrivando a 364 milioni di dollari nei primi nove mesi del 2024. Sulla base di una performance solida, QIAGEN ha confermato la previsione per le vendite nette del FY 2024 di almeno 1,985 miliardi di dollari CER e ha aumentato la previsione dell'utile per azione diluito rettificato ad almeno 2,19 dollari CER rispetto ai precedenti 2,10 dollari CER.
QIAGEN informó resultados sólidos para el tercer trimestre de 2024, con ventas netas de 502 millones de dólares, lo que representa un incremento del 5% a tipos de cambio actuales y del 6% a tipos de cambio constantes (CER), superando la previsión de 495 millones de dólares CER. La empresa logró un margen de ingresos operativos ajustados del 29,6%, un aumento de 3 puntos porcentuales respecto al tercer trimestre de 2023. El flujo de efectivo libre aumentó un 73%, alcanzando 364 millones de dólares en los primeros nueve meses de 2024. Basándose en un sólido rendimiento, QIAGEN reafirmó su previsión de ventas netas para el FY 2024 de al menos 1,985 millones de dólares CER y aumentó su previsión de EPS diluido ajustado a al menos 2,19 dólares CER, desde los previos 2,10 dólares CER.
QIAGEN은 2024년 3분기 강력한 실적을 보고하며 순매출 5억 2천만 달러를 기록했습니다. 이는 현재 환율 기준으로 5% 증가, 상수 환율(CER) 기준으로 6% 증가한 수치로, 4억 9천5백만 달러 CER의 전망치를 초과한 결과입니다. 회사는 수정된 영업 이익률 29.6%을 달성했으며, 이는 2023년 3분기 대비 3% 포인트 증가한 수치입니다. 2024년 첫 9개월 동안 자유 현금 흐름은 73% 증가하여 3억 6천4백만 달러에 달했습니다. QIAGEN은 건실한 성과를 기반으로 FY 2024 순매출 전망을 최소 19억 8천5백만 달러 CER로 재확인하고, 수정된 희석 주당 순이익 전망을 이전 2.10달러 CER에서 2.19달러 CER로 증액했습니다.
QIAGEN a annoncé de solides résultats pour le troisième trimestre 2024, avec des ventes nettes de 502 millions de dollars, représentant une augmentation de 5 % aux taux actuels et de 6 % aux taux de change constants (CER), dépassant la prévision de 495 millions de dollars CER. L'entreprise a atteint une marge de résultat opérationnel ajusté de 29,6 %, en hausse de 3 points de pourcentage par rapport au troisième trimestre 2023. Le flux de trésorerie libre a augmenté de 73 % pour atteindre 364 millions de dollars au cours des neuf premiers mois de 2024. Sur la base de performances solides, QIAGEN a réaffirmé son estimation de ventes nettes pour l'exercice 2024 d'au moins 1,985 milliard de dollars CER et a augmenté son estimation de l'EPS dilué ajusté à au moins 2,19 dollars CER, contre 2,10 dollars CER précédemment.
QIAGEN berichtete über starke Ergebnisse für das 3. Quartal 2024 mit Nettoumsätzen von 502 Millionen Dollar, was einem Anstieg von 5 % zu aktuellen Wechselkursen und 6 % zu konstanten Wechselkursen (CER) entspricht und die Prognose von 495 Millionen Dollar CER übertrifft. Das Unternehmen erzielte eine bereinigte operative Einkommensmarge von 29,6 %, was einem Anstieg um 3 Prozentpunkte im Vergleich zum 3. Quartal 2023 entspricht. Der freie Cashflow stieg in den ersten neun Monaten 2024 um 73 % auf 364 Millionen Dollar. Basierend auf einer soliden Performance bestätigte QIAGEN seine Prognose für die Nettoumsätze im Geschäftsjahr 2024 von mindestens 1,985 Milliarden Dollar CER und hebte die Prognose für das bereinigte verwässerte EPS auf mindestens 2,19 Dollar CER an, gegenüber den vorherigen 2,10 Dollar CER.
- Net sales grew 5% to $502 million, exceeding guidance
- Adjusted operating income margin improved by 3 percentage points to 29.6%
- Free cash flow increased 73% to $364 million in first nine months
- Raised full-year 2024 adjusted EPS guidance to $2.19 CER
- Diagnostic solutions achieved 10% CER growth
- None.
Insights
QIAGEN's Q3 2024 results demonstrate robust financial performance with several positive indicators. Net sales reached
- Strong
10% CER growth in Diagnostic solutions 73% increase in free cash flow to$364 million for the first nine months- Increased full-year adjusted EPS guidance to
$2.19 CER - High recurring revenue at
85% of sales indicates stable future cash flows
The company's operational efficiency initiatives and portfolio optimization, including the NeuMoDx discontinuation, are yielding positive results. The raised EPS guidance and maintained sales outlook of
Q3 2024: Net sales of
Venlo, the Netherlands, Nov. 06, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for the third quarter and first nine months of 2024.
Net sales rose
QIAGEN has reaffirmed its FY 2024 sales outlook for at least
“QIAGEN delivered another solid performance in the third quarter of 2024, exceeding our goals for net sales and adjusted earnings thanks to the strong trends in our business and the resilience of our portfolio with over
“The value of our portfolio was again underscored with three QIAGEN customers recently being awarded Nobel Prizes for their groundbreaking contributions to advancing science and improving healthcare. Our teams are constantly enhancing this portfolio, and recent developments include the launch of 100 new assays for the QIAcuity digital PCR system along with the new QIAcuityDx version for clinical applications. We have expanded the utility of our QIAstat-Dx system beyond syndromic testing through new pharma partnerships with AstraZeneca and Eli Lilly. This progress in 2024 to achieve our goals marks a key step toward achieving our 2028 targets and delivering on our commitment to solid profitable growth,” Bernard said.
“Our 2024 results to date reflect a positive quarterly trend in sales and adjusted earnings, along with a
Please find a PDF of the full press release incl. tables here.
Investor presentation and conference call
A conference call is planned for Thursday, November 7, 2024 at 15:30 Frankfurt Time / 14:30 London Time / 9:30 New York Time. A live audio webcast will be made available in the investor relations section of the QIAGEN website, and a recording will also be made available after the event. A presentation will be available before the conference call at https://corporate.qiagen.com/investor-relations/events-and-presentations/default.aspx.
Use of adjusted results
QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures (generally accepted accounting principles), to provide additional insight into its performance. These results include adjusted net sales, adjusted gross income, adjusted gross profit, adjusted operating income, adjusted operating expenses, adjusted operating income margin, adjusted net income, adjusted net income before taxes, adjusted diluted EPS, adjusted EBITDA, adjusted EPS, adjusted income taxes, adjusted tax rate, and free cash flow. Free cash flow is calculated by deducting capital expenditures for Property, Plant & Equipment from cash flow from operating activities. Adjusted results are non-GAAP financial measures that QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of ongoing core operations, vary significantly from period to period, or affect the comparability of results with competitors and its own prior periods. Furthermore, QIAGEN uses non-GAAP and constant currency financial measures internally in planning, forecasting and reporting, as well as to measure and compensate employees. QIAGEN also uses adjusted results when comparing current performance to historical operating results, which have consistently been presented on an adjusted basis.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of September 30, 2024, QIAGEN employed more than 5,800 people in over 35 locations worldwide. Further information can be found at https://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations, markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” contained in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.
Source: QIAGEN N.V.
Category: Financial
FAQ
What was QIAGEN's (QGEN) Q3 2024 revenue?
Did QIAGEN (QGEN) raise its guidance for 2024?
What was QIAGEN's (QGEN) Q3 2024 operating margin?
